Sebastian Schwind
YOU?
Author Swipe
View article: The sequence of 12 Gy total body irradiation and cyclophosphamide does not impact outcomes in AML patients receiving myeloablative allogeneic stem cell transplantation
The sequence of 12 Gy total body irradiation and cyclophosphamide does not impact outcomes in AML patients receiving myeloablative allogeneic stem cell transplantation Open
View article: Impact of cellular composition and T‐cell senescence of mononuclear cell concentrates on the manufacturing process of chimeric antigen receptor (<scp>CAR</scp>) T‐cells
Impact of cellular composition and T‐cell senescence of mononuclear cell concentrates on the manufacturing process of chimeric antigen receptor (<span>CAR</span>) T‐cells Open
Background Apheresis procedure of autologous lymphocytes competent for proliferation and expansion is a crucial step in the production of chimeric antigen receptor (CAR) T‐cells. Previous therapies or disease status prior to collection may…
View article: Sex-associated differences in outcome of patients with acute myeloid leukemia undergoing allogeneic hematopoietic stem cell transplantation
Sex-associated differences in outcome of patients with acute myeloid leukemia undergoing allogeneic hematopoietic stem cell transplantation Open
View article: Impact of Evolving <scp>WHO</scp> and <scp>ICC</scp> Classifications on Prognosis and Outcomes in <scp>AML</scp> Patients Undergoing Allogeneic Stem Cell Transplantation
Impact of Evolving <span>WHO</span> and <span>ICC</span> Classifications on Prognosis and Outcomes in <span>AML</span> Patients Undergoing Allogeneic Stem Cell Transplantation Open
View article: Hematopoietic cell transplantation for older acute myeloid leukemia patients in first complete remission: results of a randomized phase III study
Hematopoietic cell transplantation for older acute myeloid leukemia patients in first complete remission: results of a randomized phase III study Open
Given the selection of elderly patients with AML in first complete remission (CR1) the advantage of consolidation with allogeneic hematopoietic cell transplantation (HCT) over chemotherapy is still unclear. Newly diagnosed AML patients in …
View article: Red blood cell distribution width (RDW) is associated with unfavorable functional outcome after transfemoral transcatheter aortic valve implantation
Red blood cell distribution width (RDW) is associated with unfavorable functional outcome after transfemoral transcatheter aortic valve implantation Open
Elevated preprocedural RDW identifies patients at risk for impaired functional outcome after TAVI and may represent a useful low-cost parameter to guide intensity of outpatient surveillance strategies.
View article: Quantifying <i>NPM1</i> MRD in AML patients prior to allogeneic stem cell transplantation: Where to draw the line?
Quantifying <i>NPM1</i> MRD in AML patients prior to allogeneic stem cell transplantation: Where to draw the line? Open
Today, assessment of measurable residual disease (MRD) increasingly allows a dynamic risk stratification and informs treatment decisions in acute myeloid leukemia (AML).1 For AML patients with NPM1 gene mutations quantitative PCR methods h…
View article: Cellular dynamics following CAR T cell therapy are associated with response and toxicity in relapsed/refractory myeloma
Cellular dynamics following CAR T cell therapy are associated with response and toxicity in relapsed/refractory myeloma Open
View article: Prognostic impact of measurable residual clonal hematopoiesis in acute myeloid leukemia patients after allogeneic hematopoietic stem cell transplantation
Prognostic impact of measurable residual clonal hematopoiesis in acute myeloid leukemia patients after allogeneic hematopoietic stem cell transplantation Open
Graphical Abstract
View article: MicroRNA Expression Patterns Reveal a Role of the TGF-β Family Signaling in AML Chemo-Resistance
MicroRNA Expression Patterns Reveal a Role of the TGF-β Family Signaling in AML Chemo-Resistance Open
Resistance to chemotherapy is ultimately responsible for the majority of AML-related deaths, making the identification of resistance pathways a high priority. Transcriptomics approaches can be used to identify genes regulated at the level …
View article: Steady‐state versus chemotherapy‐based hematopoietic cell mobilization after <scp>anti‐CD38</scp>‐based induction therapy in newly diagnosed multiple myeloma
Steady‐state versus chemotherapy‐based hematopoietic cell mobilization after <span>anti‐CD38</span>‐based induction therapy in newly diagnosed multiple myeloma Open
Background The incorporation of anti‐CD38 monoclonal antibodies (mAb) in induction regimens of newly diagnosed transplant‐eligible multiple myeloma (MM) patients has been established as a new standard. However, the optimal strategy of stem…
View article: Cellular dynamics following CAR T cell therapy are associated with response and toxicity in relapsed/refractory myeloma
Cellular dynamics following CAR T cell therapy are associated with response and toxicity in relapsed/refractory myeloma Open
B cell maturation antigen (BCMA)-targeting chimeric antigen receptor (CAR) T cells revolutionized the treatment of relapsed/refractory multiple myeloma (RRMM). However, data on cellular (CAR) T cell dynamics and the association with respon…
View article: PB2450: SEX-ASSOCIATED OUTCOME DIFFERENCES IN PATIENTS WITH ACUTE MYELOID LEUKEMIA (AML) UNDERGOING ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION (HSCT)
PB2450: SEX-ASSOCIATED OUTCOME DIFFERENCES IN PATIENTS WITH ACUTE MYELOID LEUKEMIA (AML) UNDERGOING ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION (HSCT) Open
Topic: 22. Stem cell transplantation - Clinical Background: Recent identifications of sex-associated differences in the biology of hematologic neoplasm highlights the need to explore sex as a so far underestimated factor influencing outcom…
View article: P508: THE PROGNOSTIC SIGNIFICANCE OF THE MEASURABLE RESIDUAL DISEASE STATUS WITHIN THE THREE AML ELN2022 RISK GROUPS
P508: THE PROGNOSTIC SIGNIFICANCE OF THE MEASURABLE RESIDUAL DISEASE STATUS WITHIN THE THREE AML ELN2022 RISK GROUPS Open
Background: The 2022 updated European LeukemiaNet (ELN) risk classification for acute myeloid leukemia (AML) includes risk adjustments during disease course by measurable residual disease (MRD) assessment. While the ELN2022 classification …
View article: P1315: THE CHRONOLOGICAL SEQUENCE OF 12 GY TOTAL BODY IRRADIATION AND CYCLOPHOSPHAMIDE CONDITIONING DOES NOT IMPACT OUTCOMES IN AML PATIENTS UNDERGOING MYELOABLATIVE ALLOGENEIC STEM CELL TRANSPLANTATION
P1315: THE CHRONOLOGICAL SEQUENCE OF 12 GY TOTAL BODY IRRADIATION AND CYCLOPHOSPHAMIDE CONDITIONING DOES NOT IMPACT OUTCOMES IN AML PATIENTS UNDERGOING MYELOABLATIVE ALLOGENEIC STEM CELL TRANSPLANTATION Open
Topic: 22. Stem cell transplantation - Clinical Background: Allogeneic hematopoietic stem cell transplantion (allo-HSCT) is considered standard of care in eligible patients (pts) with acute myeloid leukemia (AML) and intermediate or advers…
View article: P497: CLINICAL OUTCOMES OF NPM1-MUTATED ACUTE MYELOID LEUKEMIA (AML) PATIENTS WITH MEASURABLE RESIDUAL DISEASE (MRD) RELAPSE AFTER ACHIEVEMENT OF A FIRST MRD-NEGATIVE REMISSION
P497: CLINICAL OUTCOMES OF NPM1-MUTATED ACUTE MYELOID LEUKEMIA (AML) PATIENTS WITH MEASURABLE RESIDUAL DISEASE (MRD) RELAPSE AFTER ACHIEVEMENT OF A FIRST MRD-NEGATIVE REMISSION Open
Background: Persisting MRD is a strong prognostic factor in NPM1-mutated (mut) AML patients (pts) and a new risk factor according to the European LeukemiaNet (ELN) 2022 classification. Data on MRD relapse in morphologic complete remission …
View article: P1415: CELLULAR DYNAMICS IN RESPONDERS AND NON-RESPONDERS AFTER THE TREATMENT OF PATIENTS WITH AGGRESSIVE B-ZELL LYMPHOMAS WITH CHIMERIC ANTIGEN RECEPTOR (CAR) T CELLS
P1415: CELLULAR DYNAMICS IN RESPONDERS AND NON-RESPONDERS AFTER THE TREATMENT OF PATIENTS WITH AGGRESSIVE B-ZELL LYMPHOMAS WITH CHIMERIC ANTIGEN RECEPTOR (CAR) T CELLS Open
Topic: 25. Gene therapy, cellular immunotherapy and vaccination - Clinical Background: Anti-CD19 Chimeric Antigen Receptor (CAR) T cells have revolutionized the treatment of patients (pts) with refractory or relapsed (r/r) aggressive B-cel…
View article: Cellular dynamics and their impact on outcome in patients with mantle cell lymphoma during treatment with chimeric antigen receptor (CAR) T cells
Cellular dynamics and their impact on outcome in patients with mantle cell lymphoma during treatment with chimeric antigen receptor (CAR) T cells Open
Introduction: Brexucabtagene autoleucel (brexu-cel) is an effective chimeric antigen receptor (CAR) product for the treatment of patients (pts) with refractory or relapsed (r/r) mantle-cell lymphoma (MCL). Cellular biomarkers predicting re…
View article: STEM CELL MOBILIZATION AND AUTOLOGOUS STEM CELL TRANSPLANTATION AFTER BENDAMUSTINE, PREDNISONE AND BORTEZOMIB INDUCTION IN MULTIPLE MYELOMA PATIENTS WITH RENAL IMPAIRMENT
STEM CELL MOBILIZATION AND AUTOLOGOUS STEM CELL TRANSPLANTATION AFTER BENDAMUSTINE, PREDNISONE AND BORTEZOMIB INDUCTION IN MULTIPLE MYELOMA PATIENTS WITH RENAL IMPAIRMENT Open
Background: High-dose therapy followed by autologous stem cell transplantation (ASCT) is the standard first line treatment for younger patients (<70 years) with multiple myeloma (MM). Approximately 20%–50% of all patients already display a…
View article: Data from Targeted Delivery of <i>microRNA-29b</i> by Transferrin-Conjugated Anionic Lipopolyplex Nanoparticles: A Novel Therapeutic Strategy in Acute Myeloid Leukemia
Data from Targeted Delivery of <i>microRNA-29b</i> by Transferrin-Conjugated Anionic Lipopolyplex Nanoparticles: A Novel Therapeutic Strategy in Acute Myeloid Leukemia Open
Purpose:miR-29b directly or indirectly targets genes involved in acute myeloid leukemia (AML), namely, DNMTs, CDK6, SP1, KIT, and FLT3. Higher miR-29b pretreatment expression is associated with imp…
View article: Supplementary Table 1, Figures 1 - 5 from Targeted Delivery of <i>microRNA-29b</i> by Transferrin-Conjugated Anionic Lipopolyplex Nanoparticles: A Novel Therapeutic Strategy in Acute Myeloid Leukemia
Supplementary Table 1, Figures 1 - 5 from Targeted Delivery of <i>microRNA-29b</i> by Transferrin-Conjugated Anionic Lipopolyplex Nanoparticles: A Novel Therapeutic Strategy in Acute Myeloid Leukemia Open
PDF file - 325K, Supplemental Table 1: Particle Size Distribution and Zeta Potential; Supplemental Figure 1: Transferrin receptor (CD71) expression on AML patient blasts; Supplemental Figure 2: miR entrapment efficiency; Supplemental Figur…
View article: Data from Targeted Delivery of <i>microRNA-29b</i> by Transferrin-Conjugated Anionic Lipopolyplex Nanoparticles: A Novel Therapeutic Strategy in Acute Myeloid Leukemia
Data from Targeted Delivery of <i>microRNA-29b</i> by Transferrin-Conjugated Anionic Lipopolyplex Nanoparticles: A Novel Therapeutic Strategy in Acute Myeloid Leukemia Open
Purpose:miR-29b directly or indirectly targets genes involved in acute myeloid leukemia (AML), namely, DNMTs, CDK6, SP1, KIT, and FLT3. Higher miR-29b pretreatment expression is associated with imp…
View article: Supplementary Table 1, Figures 1 - 5 from Targeted Delivery of <i>microRNA-29b</i> by Transferrin-Conjugated Anionic Lipopolyplex Nanoparticles: A Novel Therapeutic Strategy in Acute Myeloid Leukemia
Supplementary Table 1, Figures 1 - 5 from Targeted Delivery of <i>microRNA-29b</i> by Transferrin-Conjugated Anionic Lipopolyplex Nanoparticles: A Novel Therapeutic Strategy in Acute Myeloid Leukemia Open
PDF file - 325K, Supplemental Table 1: Particle Size Distribution and Zeta Potential; Supplemental Figure 1: Transferrin receptor (CD71) expression on AML patient blasts; Supplemental Figure 2: miR entrapment efficiency; Supplemental Figur…
View article: Single cell multi-omic dissection of response and resistance to chimeric antigen receptor T cells against BCMA in relapsed multiple myeloma
Single cell multi-omic dissection of response and resistance to chimeric antigen receptor T cells against BCMA in relapsed multiple myeloma Open
Markers predicting response and resistance to chimeric antigen receptor (CAR) T cells in relapsed/refractory multiple myeloma are currently missing. We subjected cells isolated from peripheral blood and bone marrow before and after the app…
View article: Clinical Implications of the FLT3-ITD Allelic Ratio in Acute Myeloid Leukemia in the Context of an Allogeneic Stem Cell Transplantation
Clinical Implications of the FLT3-ITD Allelic Ratio in Acute Myeloid Leukemia in the Context of an Allogeneic Stem Cell Transplantation Open
Although the presence of FLT3-ITD, as well as levels of the FLT3-ITD allelic ratio, have been described as prognostic factors in acute myeloid leukemia (AML), little is known about how the FLT3-ITD allelic ratio impacts patients’ outcomes …
View article: Different treatment strategies versus a common standard arm (CSA) in patients with newly diagnosed AML over the age of 60 years: a randomized German inter-group study
Different treatment strategies versus a common standard arm (CSA) in patients with newly diagnosed AML over the age of 60 years: a randomized German inter-group study Open
View article: Prognostic value of baseline and early response FDG-PET/CT in patients with refractory and relapsed aggressive B-cell lymphoma undergoing CAR-T cell therapy
Prognostic value of baseline and early response FDG-PET/CT in patients with refractory and relapsed aggressive B-cell lymphoma undergoing CAR-T cell therapy Open
View article: Prognostic impact of the AML ELN2022 risk classification in patients undergoing allogeneic stem cell transplantation
Prognostic impact of the AML ELN2022 risk classification in patients undergoing allogeneic stem cell transplantation Open
View article: A high hematopoietic cell transplantation comorbidity Index (HCT-CI) does not impair outcomes after non-myeloablative allogeneic stem cell transplantation in acute myeloid leukemia patients 60 years or older
A high hematopoietic cell transplantation comorbidity Index (HCT-CI) does not impair outcomes after non-myeloablative allogeneic stem cell transplantation in acute myeloid leukemia patients 60 years or older Open
View article: Compartment-specific mutational landscape of clonal hematopoiesis
Compartment-specific mutational landscape of clonal hematopoiesis Open